Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Conclusion
There was an increased risk of cutaneous AEs with daclizumab HYP. While physicians should be aware of the potential for serious cutaneous AEs, the typical cutaneous AEs were mild-to-moderate in severity, manageable, and resolved over time.
Funding
Biogen and AbbVie Biotherapeutics Inc.
Trial registration
ClinicalTrials.gov identifier, NCT01064401.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Avonex | Corticosteroid Therapy | Drugs & Pharmacology | Eczema | Multiple Sclerosis | Rebif | Skin | Study